Plain-English translation of NCT05083247 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether adding a focused, high-dose radiation treatment called isotoxic high-dose stereotactic body radiation therapy (iHD-SBRT) to chemotherapy before surgery can help people with borderline resectable pancreatic cancer. All patients will first receive chemotherapy — either mFOLFIRINOX or gemcitabine with Abraxane — to shrink the tumor. Then, doctors will decide if the cancer is ready for surgery or if it would benefit from the radiation treatment to improve the chances of successful removal.
Borderline resectable pancreatic cancer is difficult to treat because the tumor is touching important blood vessels, making surgery risky. This trial is testing whether adding focused radiation before surgery can help shrink the tumor more effectively and make it safer and easier for surgeons to remove completely.
You likely qualify if…
You likely don't qualify if…
You will start with four cycles of chemotherapy given intravenously every two weeks. After this, doctors will do imaging scans and blood tests to see how the cancer has responded. If your cancer has not gotten worse, you will be randomly assigned to one of two groups: one group will continue with additional chemotherapy cycles followed by surgery, while the other group will receive more chemotherapy plus focused radiation therapy to the tumor, followed by additional chemotherapy and then surgery. The entire treatment process will take several months, with regular clinic visits for chemotherapy infusions, imaging scans, and blood work.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
Belgium